THERAVECTYS is a privately-owned company located in France, translating 20 years+ of research on lentiviral vectors into actionable innovation and bringing a spectacular paradigm shift into vaccinology. Founded by pioneer inventor Dr Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver remarkably safe and efficient T-cell vaccines as a response to critical unmet medical needs. THERAVECTYS’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is probably the biggest silent revolution in vaccination
since the discovery of the vaccine against rabies by Louis Pasteur. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine-candidates to clinical trials and to market.